353 related articles for article (PubMed ID: 16962614)
1. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain.
Inceoglu B; Jinks SL; Schmelzer KR; Waite T; Kim IH; Hammock BD
Life Sci; 2006 Nov; 79(24):2311-9. PubMed ID: 16962614
[TBL] [Abstract][Full Text] [Related]
2. Omeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE₂ induced pain model.
Goswami SK; Inceoglu B; Yang J; Wan D; Kodani SD; da Silva CA; Morisseau C; Hammock BD
Toxicol Appl Pharmacol; 2015 Dec; 289(3):419-27. PubMed ID: 26522832
[TBL] [Abstract][Full Text] [Related]
3. The oxidized linoleic acid metabolite 12,13-DiHOME mediates thermal hyperalgesia during inflammatory pain.
Zimmer B; Angioni C; Osthues T; Toewe A; Thomas D; Pierre SC; Geisslinger G; Scholich K; Sisignano M
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Jul; 1863(7):669-678. PubMed ID: 29625231
[TBL] [Abstract][Full Text] [Related]
4. Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception.
Wagner K; Inceoglu B; Hammock BD
Prostaglandins Other Lipid Mediat; 2011 Nov; 96(1-4):76-83. PubMed ID: 21854866
[TBL] [Abstract][Full Text] [Related]
5. Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive.
Sasso O; Wagner K; Morisseau C; Inceoglu B; Hammock BD; Piomelli D
Pharmacol Res; 2015 Jul; 97():7-15. PubMed ID: 25882247
[TBL] [Abstract][Full Text] [Related]
6. Targeting soluble epoxide hydrolase for inflammation and pain - an overview of pharmacology and the inhibitors.
Pillarisetti S; Khanna I
Inflamm Allergy Drug Targets; 2012 Apr; 11(2):143-58. PubMed ID: 22280237
[TBL] [Abstract][Full Text] [Related]
7. The soluble epoxide hydrolase as a pharmaceutical target for hypertension.
Chiamvimonvat N; Ho CM; Tsai HJ; Hammock BD
J Cardiovasc Pharmacol; 2007 Sep; 50(3):225-37. PubMed ID: 17878749
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor.
Smith KR; Pinkerton KE; Watanabe T; Pedersen TL; Ma SJ; Hammock BD
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2186-91. PubMed ID: 15684051
[TBL] [Abstract][Full Text] [Related]
9. The weakening effect of soluble epoxide hydrolase inhibitor AUDA on febrile response to lipopolysaccharide and turpentine in rat.
Piotrowski J; Jędrzejewski T; Pawlikowska M; Pacuła AJ; Ścianowski J; Kozak W
J Physiol Biochem; 2017 Nov; 73(4):551-560. PubMed ID: 28741242
[TBL] [Abstract][Full Text] [Related]
10. Measurement of soluble epoxide hydrolase (sEH) activity.
Morisseau C; Hammock BD
Curr Protoc Toxicol; 2007; Chapter 4():Unit 4.23. PubMed ID: 23045145
[TBL] [Abstract][Full Text] [Related]
11. Meloxicam fails to augment the reno-protective effects of soluble epoxide hydrolase inhibition in streptozotocin-induced diabetic rats via increased 20-HETE levels.
Katary MM; Pye C; Elmarakby AA
Prostaglandins Other Lipid Mediat; 2017 Sep; 132():3-11. PubMed ID: 27596333
[TBL] [Abstract][Full Text] [Related]
12. Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.
Wagner K; Yang J; Inceoglu B; Hammock BD
J Pain; 2014 Sep; 15(9):907-14. PubMed ID: 24924124
[TBL] [Abstract][Full Text] [Related]
13. Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase/fatty acid amide hydrolase inhibitors.
Wilt S; Kodani S; Valencia L; Hudson PK; Sanchez S; Quintana T; Morisseau C; Hammock BD; Kandasamy R; Pecic S
Bioorg Med Chem; 2021 Dec; 51():116507. PubMed ID: 34794001
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models.
Wagner K; Inceoglu B; Dong H; Yang J; Hwang SH; Jones P; Morisseau C; Hammock BD
Eur J Pharmacol; 2013 Jan; 700(1-3):93-101. PubMed ID: 23276668
[TBL] [Abstract][Full Text] [Related]
15. Central and local administration of Gingko biloba extract EGb 761® inhibits thermal hyperalgesia and inflammation in the rat carrageenan model.
Thorpe LB; Goldie M; Dolan S
Anesth Analg; 2011 May; 112(5):1226-31. PubMed ID: 21474665
[TBL] [Abstract][Full Text] [Related]
16. Epoxygenated fatty acids and soluble epoxide hydrolase inhibition: novel mediators of pain reduction.
Wagner K; Inceoglu B; Gill SS; Hammock BD
J Agric Food Chem; 2011 Apr; 59(7):2816-24. PubMed ID: 20958046
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation.
Fife KL; Liu Y; Schmelzer KR; Tsai HJ; Kim IH; Morisseau C; Hammock BD; Kroetz DL
J Pharmacol Exp Ther; 2008 Dec; 327(3):707-15. PubMed ID: 18815352
[TBL] [Abstract][Full Text] [Related]
18. Screening of soluble epoxide hydrolase inhibitory ingredients from traditional Chinese medicines for anti-inflammatory use.
Liu JY; Morisseau C; Huang H; Hammock BD
J Ethnopharmacol; 2016 Dec; 194():475-482. PubMed ID: 27702689
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.
Revermann M
Curr Opin Pharmacol; 2010 Apr; 10(2):173-8. PubMed ID: 20079692
[TBL] [Abstract][Full Text] [Related]
20. Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders.
Zarriello S; Tuazon JP; Corey S; Schimmel S; Rajani M; Gorsky A; Incontri D; Hammock BD; Borlongan CV
Prog Neurobiol; 2019 Jan; 172():23-39. PubMed ID: 30447256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
